Avid Bioservices Inc (CDMO)

[biopharm]

From Russia.. With Love? Part IV:

More comments on the Affitech partership and Affitech break up and going private and the only way to see if any agendas were in play is to possibly start with who is left standing at the BOD positions in Affitech .....

Aleksandr Shuster
Andrei Petrov
Igor Fisch
Steven Morrell
Yegor S. Vassetzky

http://www.affitech.com/node/340
------------------------------------------------------------------

Whom shall we start with.... lets take "Igor Fisch":

Igor Fisch, PhD, CEO

Dr. Igor Fisch co-founded Selexis SA in March 2001 and has been the company’s Chairman and CEO since its inception.

Igor is a member of the Board of Directors of Affitech A/S, a biopharmaceutical company listed on NASDAQ OMX Copenhagen, dedicated to the discovery and development of human antibody based therapeutics. He co-founded BioXpress SA, a provider of high-quality biosmilars. and sits on its Advisory Board. He previously was a Board Member of Viroblock SA, a company that he helped create, which is developing a unique range of proprietary anti-viral products. Igor is on the board of the Venture kick initiative, which provides support and funding to translate promising business ideas from Swiss Universities into start-up companies.

An accomplished protein chemist and molecular biologist, Igor previously was a professor at the Center for Biotechnology at the University of Lausanne and the EPFL. He obtained his PhD under the direction of Professor Robin Offord at the University of Geneva and pursued his post-doctoral studies in the laboratory of Prof. Sir Gregory Winter at the Medical Research Council (MRC) in Cambridge, UK. In parallel to his research and teaching activities, Igor obtainedseveral awards including the De Vigier Prize and the NETS Best Prize.

http://www.selexis.com/-Management-

http://www3.unil.ch/wpmu/lifesciencecareerday/files/2013/04/Biosketchs_Preliminary-version-web.pdf
----------------------------------------------------------------

Back to Affitech for a second... we also have "Alexander Duncan":

Alex gained his PhD in Dr. Sir Greg Winter's laboratory at the MRC Laboratory of Molecular Biology, University of Cambridge and held post-doctoral positions at the University of California San Diego.

http://www.affitech.com/about-us/executive-management/alexander-duncan
----------------------------------------------------------------

Now, how does one become a Board Member of Affitech? Of course it is by what circles you travel in and we have Selexis

"Dr. Igor Fisch co-founded Selexis SA in March 2001 and has been the company’s Chairman and CEO since its inception."

Next.... Selexis becomes the focus:
------------------------------------------------------------------

Selexis Establishes US Subsidiary and Appoints Andrew F. Sandford Vice-President of Business Development and Licensing

April 10, 2007

Most recently, Sandford was part of the business development group at Cambrex Biopharma, which is now part of Lonza Biologics.

http://www.selexis.com/Selexis-Establishes-US-Subsidiary
-----------------------------------------------------------------

Now... the puzzle pieces get interesting at this point, because Andrew Sandford leaves Lonza--- but for what reasons? possibly only because Peregrine and Lonza finalized their partnering agreements but some were filed under "CTO's" at this time... in 2007 and I imagine Mr. Sandford was welcomed into Selexis as some probably had plenty of questions regarding what Peregrine was up to way back in 2007...

....Supported transactional and limited strategic initiatives during transitional period......

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88340760
-----------------------------------------------------------------

That was way back in 2007 till now.... where Peregrine has carved their path carefully and with several attempts to force them off the road by someone that looked to be driving from right side of the vehicle.

Who is going to travel this path with Peregrine?... where the possible forward generating revenues from the anti-PS platform will have Charles Duncan saying: "Great quarter!" ... "Impressive quarter!" ... every time he hops on a Peregrine quarterly cc

May historic data... bring us historic market caps.

GLTA!